表达PspA-PdT融合蛋白的重组卡介苗以初免-加强策略保护小鼠抵抗肺炎链球菌致死性攻击
研究将PspA-PdT融合蛋白导入具有佐剂特性的卡介苗(BCG)构建重组BCG,在小鼠中采用初免-加强策略(重组BCG初免、rPspA-PdT加强)免疫,诱导针对两种蛋白的抗体反应并促进IgG1向IgG2同种型转换,血清抗体可结合肺炎链球菌表面并增强补体沉积,且保护小鼠抵抗致死性攻击。
要点
- 重组BCG PspA-PdT初免加rPspA-PdT加强可诱导针对PspA和PdT两种蛋白的抗体反应。
- 该策略促进IgG1向IgG2抗体同种型转换,血清抗体可结合肺炎链球菌表面并增强补体沉积。
- 该初免-加强策略保护小鼠抵抗肺炎链球菌致死性攻击,支持进一步研究重组BCG表达肺炎链球菌蛋白。
核心结论
- 重组BCG PspA-PdT/rPspA-PdT初免-加强策略可诱导保护性免疫并保护小鼠抵抗肺炎链球菌致死性攻击,结果支持进一步研究重组BCG株表达肺炎链球菌蛋白。
研究设计与样本
- 小鼠免疫实验:以表达PspA-PdT融合蛋白的重组BCG(rBCG PspA-PdT)初免,以纯化rPspA-PdT蛋白加强,并与WT-BCG/rPspA-PdT或单剂rPspA-PdT比较。
主要发现
- rBCG PspA-PdT/rPspA-PdT免疫小鼠可诱导针对PspA和PdT两种蛋白的抗体反应,并促进IgG1向IgG2抗体同种型转换。
- 与WT-BCG/rPspA-PdT或单剂rPspA-PdT相比,rBCG PspA-PdT/rPspA-PdT免疫小鼠血清抗体可结合肺炎链球菌表面并促进更高的补体沉积。
- 上述抗血清可抑制肺炎链球菌溶血素(Ply)的细胞溶解活性。
- 脾细胞培养中白细胞介素-6(IL-6)、γ干扰素(IFN-γ)和肿瘤坏死因子α(TNF-α)产生增加。
- 在蛋白加强剂量前后,rBCG PspA-PdT免疫小鼠脾脏CD4+ T细胞上早期活化分子CD69表达更高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pneumococcal proteins have been evaluated as genetically-conserved potential vaccine candidates. We have previously demonstrated that a fragment of PspA in fusion with PdT (rPspA-PdT) induced protective immune responses in mice. However, purified proteins have shown poor immunogenicity and often require the combination with strong adjuvants and booster doses. Here, we investigated the use of a Bacillus Calmette-Guérin (BCG) strain, a well-established prophylactic vaccine for tuberculosis with known adjuvant properties, for delivery of the PspA-PdT fusion protein. Immunization of mice in a prime-boost strategy, using rPspA-PdT as a boost, demonstrated that rBCG PspA-PdT/rPspA-PdT was able to induce an antibody response against both proteins, promoting an IgG1 to IgG2 antibody isotype shift. Sera from rBCG PspA-PdT/rPspA-PdT immunized mice showed antibodies able to bind to the pneumococcal surface and promoted higher complement deposition when compared with WT-BCG/rPspA-PdT or a single dose of rPspA-PdT. In addition, these antisera inhibited the cytolytic activity of Ply. Production of interleukin-6 (IL-6), gamma interferon (IFN-γ), and tumor necrosis factor alpha (TNF-α) was increased in splenocytes culture. Furthermore, a higher expression of CD69 early activation molecule was observed on splenic CD4+ T cells from mice immunized with rBCG PspA-PdT before and after the protein booster dose. Finally, immunization with rBCG PspA-PdT/rPspA-PdT protected mice against pneumococcal lethal challenge. These results support the further investigation of recombinant BCG strains to express pneumococcal proteins, which could be administered in early stages of life and lead to protective pneumococcal immunity in infants and children.
引用
- Goulart C, Rodriguez D, Kanno AI, et al. Recombinant BCG expressing a PspA-PdT fusion protein protects mice against pneumococcal lethal challenge in a prime-boost strategy. Vaccine. 2017. PMID: 28242071. doi:10.1016/j.vaccine.2017.02.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。